Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations.
Asia
/ epidemiology
Body Weight
/ drug effects
Comorbidity
Diabetes Mellitus, Type 2
/ drug therapy
Humans
Hyperglycemia
/ drug therapy
Hypoglycemic Agents
/ therapeutic use
Obesity
/ drug therapy
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 Inhibitors
Diabetes mellitus, type 2
Obesity
Sodium-glucose transporter 2 inhibitors
Journal
Diabetes & metabolism journal
ISSN: 2233-6087
Titre abrégé: Diabetes Metab J
Pays: Korea (South)
ID NLM: 101556588
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
05
11
2019
accepted:
15
01
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
16
6
2021
Statut:
ppublish
Résumé
The prevalence of obesity in Asia is of epidemic proportions, with an estimated 1 billion overweight/obese individuals in the region. The majority of patients with type 2 diabetes mellitus (T2DM) are overweight/obese, which increases the risk of cardiorenal outcomes in these patients; hence, sustained reductions in body weight and visceral adiposity are important management goals. However, most of the glucose-lowering therapies such as insulin, sulfonylureas, glinides, and thiazolidinediones induce weight gain, which makes the management of overweight/obese T2DM patients challenging. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the only oral glucose-lowering agents that have been shown to reduce body weight and visceral adiposity. In addition, SGLT-2 inhibitors therapy reduces ectopic fat deposition and improves adipose tissue function and weight-related quality of life. In this article, we aim to consolidate the existing literature on the effects of SGLT-2 inhibitors in Asian patients with T2DM and to produce clinical recommendations on their use in overweight or obese patients with T2DM. Recommendations from international and regional guidelines, as well as published data from clinical trials in Asian populations and cardiovascular outcomes trials are reviewed. Based on the available data, SGLT-2 inhibitors represent an evidence-based therapeutic option for the management of overweight/obese patients with T2DM.
Identifiants
pubmed: 32097996
pii: 44.11
doi: 10.4093/dmj.2019.0208
pmc: PMC7043991
doi:
Substances chimiques
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-32Informations de copyright
Copyright © 2020 Korean Diabetes Association.
Déclaration de conflit d'intérêts
The development of these expert recommendations was supported by an unrestricted educational grant from AstraZeneca Ltd, who had no influence on the content. All authors have read, approved, and take full responsibility for the accuracy of the content.
Références
Nutr Diabetes. 2011 May 09;1:e6
pubmed: 23449381
Diabetes Obes Metab. 2014 Jul;16(7):645-50
pubmed: 24443876
Nat Rev Endocrinol. 2011 May 10;7(8):456-65
pubmed: 21556019
JAMA. 2010 Apr 14;303(14):1410-8
pubmed: 20388897
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Diabetes Investig. 2016 Jul;7(4):555-64
pubmed: 27181422
Circulation. 2005 Aug 9;112(6):900-5
pubmed: 16061741
Diabetes Obes Metab. 2017 Oct;19(10):1397-1407
pubmed: 28371205
Cardiovasc Diabetol. 2017 Mar 3;16(1):32
pubmed: 28253918
Lancet Diabetes Endocrinol. 2014 Nov;2(11):911-22
pubmed: 24731666
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966
pubmed: 16034881
Endocr Pract. 2018 Jan;24(1):91-120
pubmed: 29368965
Eur Respir Rev. 2013 Sep 1;22(129):353-64
pubmed: 23997062
Diabetes Obes Metab. 2015 Jan;17(1):23-31
pubmed: 25175734
Clin Endocrinol (Oxf). 2010 Jul;73(1):35-40
pubmed: 19832855
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Arch Intern Med. 2009 Jan 26;169(2):163-71
pubmed: 19171813
Diabetes Care. 2015 Sep;38(9):1730-5
pubmed: 26180105
J Diabetes Investig. 2016 May;7(3):366-73
pubmed: 27330723
Obes Rev. 2015 Dec;16(12):1071-80
pubmed: 26345590
Diabetes Obes Metab. 2017 Jun;19(6):874-882
pubmed: 28177187
Diabetes Obes Metab. 2013 Dec;15(12):1136-45
pubmed: 23782594
Diab Vasc Dis Res. 2015 Mar;12(2):90-100
pubmed: 25589482
Diabetes Care. 2016 Jul;39(7):1108-14
pubmed: 27289126
Nat Med. 2015 May;21(5):512-7
pubmed: 25894829
Expert Opin Pharmacother. 2018 Feb;19(3):189-201
pubmed: 29185822
Cardiovasc Diabetol. 2016 Jun 18;15:89
pubmed: 27316668
Int J Clin Pract. 2016 Sep;70(9):775-85
pubmed: 27600862
Diabetes Obes Metab. 2014 Nov;16(11):1102-10
pubmed: 24909293
Obesity (Silver Spring). 2018 Jan;26(1):70-80
pubmed: 29165885
Int J Endocrinol. 2012;2012:983814
pubmed: 22675355
J Clin Invest. 2014 Feb;124(2):499-508
pubmed: 24463454
J Diabetes Investig. 2018 Mar;9(2):332-340
pubmed: 28502112
N Engl J Med. 2006 Dec 7;355(23):2427-43
pubmed: 17145742
Diabetes Obes Metab. 2017 Apr;19(4):562-570
pubmed: 27987240
JAMA. 2014 Sep 3;312(9):934-42
pubmed: 25182102
Expert Opin Pharmacother. 2014 Aug;15(11):1501-15
pubmed: 25010793
Diabetes Metab J. 2019 Aug;43(4):398-406
pubmed: 31441247
J Diabetes Investig. 2015 Jul;6(4):443-53
pubmed: 26221523
Lancet. 2005 Oct 8;366(9493):1279-89
pubmed: 16214598
Endocrinology. 2016 Mar;157(3):1029-42
pubmed: 26713783
J Diabetes Investig. 2014 Jul;5(4):382-91
pubmed: 25411597
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Stroke. 2007 Jun;38(6):1744-51
pubmed: 17431205
Diabetes Metab Res Rev. 2016 Jul;32(5):442-58
pubmed: 27464265
Diabetes Obes Metab. 2015 Mar;17(3):304-8
pubmed: 24919820
J Diabetes. 2017 Aug;9(8):787-799
pubmed: 27625142
Clin Ther. 2014 Jan 1;36(1):84-100.e9
pubmed: 24378206
Diabetes Ther. 2014 Dec;5(2):415-33
pubmed: 25341477
Diabetes Care. 2019 Jan;42(Suppl 1):S1-S2
pubmed: 30559224
J Diabetes. 2011 Jun;3(2):109-18
pubmed: 21599865
Expert Opin Pharmacother. 2017 Oct;18(14):1433-1438
pubmed: 28770629
Diabetes Obes Metab. 2019 Aug;21(8):1990-1995
pubmed: 30993861
Endocr J. 2015;62(7):593-603
pubmed: 25971406
Adv Ther. 2014 Jun;31(6):621-38
pubmed: 24958326
JACC Heart Fail. 2016 Dec;4(12):911-919
pubmed: 27908389
J Diabetes Investig. 2015 Mar;6(2):210-8
pubmed: 25802729
Cardiovasc Diabetol. 2014 Mar 28;13:65
pubmed: 24678906
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
J Diabetes Investig. 2017 Nov;8(6):766-775
pubmed: 28107773
BMC Cardiovasc Disord. 2014 May 03;14:61
pubmed: 24884382
Diabetes Care. 2018 Aug;41(8):1801-1808
pubmed: 29895557
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Diabetes Obes Metab. 2016 Dec;18(12):1207-1216
pubmed: 27436788
Diabetes Obes Metab. 2016 Oct;18(10):1045-9
pubmed: 27265507
Indian J Endocrinol Metab. 2016 May-Jun;20(3):372-80
pubmed: 27186557
Diabetes Res Clin Pract. 2007 Jan;75(1):72-80
pubmed: 16735075
BMJ. 2012 Mar 12;344:e1369
pubmed: 22411919
Asia Pac J Clin Nutr. 2006;15(3):287-92
pubmed: 16837418
Diabetes Obes Metab. 2019 Nov;21(11):2354-2367
pubmed: 31264765
Med Clin North Am. 2013 Jan;97(1):59-74
pubmed: 23290730
Diabetes Care. 2017 Oct;40(10):1364-1372
pubmed: 28751548
J Diabetes. 2018 Jul;10(7):589-599
pubmed: 29215189
Diabetes Obes Metab. 2018 May;20(5):1176-1185
pubmed: 29316236
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Vasc Health Risk Manag. 2009;5(4):577-85
pubmed: 19649308
Diabetes Obes Metab. 2018 Jul;20(7):1770-1775
pubmed: 29473709
J Diabetes. 2016 Nov;8(6):796-808
pubmed: 26589253
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023
pubmed: 24239920
N Engl J Med. 2013 Jul 11;369(2):145-54
pubmed: 23796131
Am J Kidney Dis. 2003 Apr;41(4):733-41
pubmed: 12666059
Diabetes. 2016 Sep;65(9):2784-94
pubmed: 27381369
Eur J Clin Invest. 2004 Aug;34(8):535-42
pubmed: 15305887
Intern Med. 2016;55(22):3239-3245
pubmed: 27853064
Postgrad Med J. 2006 Apr;82(966):280-4
pubmed: 16597817
Patient. 2018 Jun;11(3):341-352
pubmed: 29313267
PLoS One. 2012;7(6):e39062
pubmed: 22745703
Adv Ther. 2015 Apr;32(4):306-18
pubmed: 25845768
Diabetes Obes Metab. 2015 Jul;17(7):665-74
pubmed: 25772548
Diabetologia. 2015 Mar;58(3):429-42
pubmed: 25583541
Diabetes Care. 2004 Jun;27(6):1265-70
pubmed: 15161773
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
Diabetes Obes Metab. 2013 May;15(5):432-40
pubmed: 23194084
Circulation. 2007 Oct 23;116(17):1942-51
pubmed: 17965405
Diabetes Care. 2016 Nov;39(11):2036-2041
pubmed: 27561923
Int J Epidemiol. 2004 Aug;33(4):751-8
pubmed: 15105409
Obesity (Silver Spring). 2012 Apr;20(4):783-93
pubmed: 22016099
QJM. 2013 Oct;106(10):933-42
pubmed: 23696677
N Engl J Med. 2012 Mar 29;366(13):1209-17
pubmed: 22455415
J Clin Med Res. 2016 Nov;8(11):805-814
pubmed: 27738482
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
Diabetes Obes Metab. 2015 Oct;17(10):984-93
pubmed: 26179482
Lancet Diabetes Endocrinol. 2018 Jun;6(6):e6-e15
pubmed: 29803268
EBioMedicine. 2017 Jun;20:137-149
pubmed: 28579299
Diabetes Obes Metab. 2018 Jan;20(1):77-84
pubmed: 28608617
Drugs R D. 2016 Sep;16(3):255-261
pubmed: 27333994
Lancet Diabetes Endocrinol. 2014 Oct;2(10):801-9
pubmed: 25127483
Int J Epidemiol. 2007 Feb;36(1):220-5
pubmed: 17510078
Endocr J. 2016 Jun 30;63(6):589-96
pubmed: 27052123
J Atheroscler Thromb. 2018 Jun 1;25(6):467-476
pubmed: 29225209
Clin J Am Soc Nephrol. 2011 Oct;6(10):2364-73
pubmed: 21852664
Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):50-55
pubmed: 31016153
N Engl J Med. 2002 Nov 14;347(20):1557-65
pubmed: 12432042
Diabetes Obes Metab. 2018 Nov;20(11):2642-2652
pubmed: 29934972
Circ J. 2016 Oct 25;80(11):2277-2281
pubmed: 27599528
Stroke. 2011 Oct;42(10):2872-7
pubmed: 21836099
Curr Med Res Opin. 2018 Jun;34(6):981-994
pubmed: 29448833
J Formos Med Assoc. 2020 Feb;119(2):577-586
pubmed: 30952480
Int J Epidemiol. 2007 Feb;36(1):226-7
pubmed: 17213213
Diabetol Metab Syndr. 2018 Mar 1;10:11
pubmed: 29507611
Diabetes Ther. 2017 Aug;8(4):851-861
pubmed: 28616806
Ann Intern Med. 2007 Sep 18;147(6):386-99
pubmed: 17638715
J Clin Endocrinol Metab. 2011 Jun;96(6):1654-63
pubmed: 21602457
Obesity (Silver Spring). 2011 Jan;19(1):83-93
pubmed: 20559303
Diabetes Obes Metab. 2018 Apr;20(4):812-820
pubmed: 29110384
Obes Rev. 2018 Dec;19(12):1630-1641
pubmed: 30253050
Lancet Diabetes Endocrinol. 2016 Nov;4(11):913-921
pubmed: 27595918
J Urol. 2012 Mar;187(3):939-44
pubmed: 22264468
Diabetes Care. 1999 Dec;22(12):1971-7
pubmed: 10587828
Diabetes Metab J. 2019 Aug;43(4):487-494
pubmed: 31339012
Ann Med. 2012 Jun;44(4):375-93
pubmed: 21495788
Arch Intern Med. 2009 Sep 28;169(17):1619-26
pubmed: 19786682
Lipids Health Dis. 2015 Sep 29;14:121
pubmed: 26415887